文献速递间质性肺疾病

CYFRA 21-1可预测特发性肺纤维化进展:PROFILE队列前瞻性纵向分析

CYFRA 21-1 Predicts Progression in Idiopathic Pulmonary Fibrosis: A Prospective Longitudinal Analysis of the PROFILE Cohort.
PubMed 文献 · Am J Respir Crit Care Med · 2022-01-01

研究基于PROFILE队列491例新诊断IPF患者及100名对照,评估血清CYFRA 21-1与疾病进展及死亡的关系。发现IPF患者CYFRA 21-1显著高于对照,基线水平可区分12个月进展风险并预测总体死亡率,3个月变化亦独立预测生存。

要点

  • IPF患者血清CYFRA 21-1显著高于健康对照。
  • 基线CYFRA 21-1可区分12个月进展风险并预测死亡。
  • 3个月CYFRA 21-1变化独立预测12个月及总体生存。

核心结论

  • CYFRA 21-1作为上皮损伤与周转标志物,可能成为IPF重要的预后和治疗生物标志物。

研究设计与样本

  • 前瞻性纵向分析PROFILE队列,纳入491例新诊断IPF患者和100名基线对照,随访至少3年。
  • 通过免疫组化在手术肺组织定位CYFRA 21-1,用ELISA检测基线、1个月和3个月血清浓度。

主要发现

  • 发现队列(n=132)对照CYFRA 21-1为0.96±0.81 ng/ml,IPF为2.34±2.15 ng/ml,P<0.0001。
  • 验证队列(n=359)对照为2.21±1.54 ng/ml,IPF为4.13±2.77 ng/ml,P<0.0001。
  • 基线CYFRA 21-1区分12个月疾病进展的C统计量为0.70(95%CI 0.61-0.79,P<0.0001)。
  • 基线CYFRA 21-1预测总体死亡的风险比1.12(95%CI 1.06-1.19,每增加1 ng/ml,P=0.0001)。
  • 3个月CYFRA 21-1变化在发现和验证队列中均独立预测12个月及总体生存。

临床怎么用

  • 可考虑检测基线及3个月血清CYFRA 21-1辅助评估IPF进展与死亡风险。
  • CYFRA 21-1动态变化可能帮助识别高风险患者以优化治疗决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: Idiopathic pulmonary fibrosis (IPF) is a progressive and inevitably fatal condition for which there are a lack of effective biomarkers to guide therapeutic decision making. Objectives: To determine the relationship between serum concentrations of the cytokeratin fragment CYFRA 21-1 and disease progression and mortality in individuals with IPF enrolled in the Prospective Observation of Fibrosis in the Lung Clinical Endpoints (PROFILE) study. Methods: CYFRA 21-1 was identified by immunohistochemistry in samples of human lung obtained at surgery. Concentrations of CYFRA 21-1 were measured using an ELISA-based assay in serum samples collected at baseline, 1 month, and 3 months from 491 individuals with an incident diagnosis of IPF who were enrolled in the PROFILE study and from 100 control subjects at baseline. Study subjects were followed for a minimum of 3 years after their first blood draw. Measurements and Main Results: CYFRA 21-1 localizes to hyperplastic epithelium in IPF lung tissue. Peripheral CYFRA 21-1 concentrations were significantly higher in subjects with IPF than in healthy control subjects in both the discovery (n = 132) (control: 0.96 ± 0.81 ng/ml; vs. IPF: 2.34 ± 2.15 ng/ml; P < 0.0001) and validation (n = 359) (control: 2.21 ± 1.54 ng/ml; and IPF: 4.13 ± 2.77 ng/ml; P < 0.0001) cohorts. Baseline concentrations of CYFRA 21-1 were able to distinguish individuals at risk of 12-month disease progression (C-statistic, 0.70; 95% confidence interval, 0.61-0.79; P < 0.0001) and were predictive of overall mortality (hazard ratio, 1.12 [95% confidence interval, 1.06-1.19] per 1 ng/ml increase in CYFRA 21-1; P = 0.0001). Furthermore, 3-month change in concentrations of CYFRA 21-1 separately predicted 12-month and overall survival in both the discovery and validation cohorts. Conclusions: CYFRA 21-1, a marker of epithelial damage and turnover, has the potential to be an important prognostic and therapeutic biomarker in individuals with IPF.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Molyneaux PL, Fahy WA, Byrne AJ, et al. CYFRA 21-1 Predicts Progression in Idiopathic Pulmonary Fibrosis: A Prospective Longitudinal Analysis of the PROFILE Cohort. Am J Respir Crit Care Med. 2022. PMID: 35363592. doi:10.1164/rccm.202107-1769OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。